FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894985356> ?p ?o ?g. }

• W2894985356 endingPage "147" @default.
• W2894985356 startingPage "135" @default.
• W2894985356 abstract "Risperidone, one of the second-generation antipsychotics, can efficiently target dopamine D2 and serotonin 5-HT2A receptors. There actually exists significant implication of CYP2D6 genetic polymorphisms on the metabolic kinetics of risperidone, little is known about the extent of CYP2D6 impacting human D2 and 5-HT2A receptor occupancies as well as the clinical efficacy and efficacy in schizophrenia treatment. Here we assessed the influences of CYP2D6 gene polymorphisms on human target occupancies/clinical outcomes and optimized the maintenance therapy of risperidone. A translational framework, previously developed using in vitro and in vivo information in rats, was used as the basis for integrating the effects of CYP2D6 genetic polymorphisms on target occupancies and clinical outcomes. D2 occupancy as a biomarker was related to Positive and Negative Syndrome Scale (PANSS) response and Simpson-Angus Scale (SAS). The population approach was applied to characterize pharmacokinetic and pharmacodynamic (PK/PD) profiles of risperidone. Non-compartment analysis method was performed to calculate the steady state PK/PD parameters of both risperidone and 9-hydroxyrisperidone. The predictive power of this extended translational framework was determined by comparing the predictions of target occupancies and clinical outcomes with the reported human values of risperidone at clinically suggested dosage of 4.0 mg/day. This extended translational framework was adequately used to predict human target occupancies and clinical outcomes. At the steady state, D2 ROs were 75.8%, 79.3% and 86.0% for CYP2D6 poor metabolizer (PM), intermediate metabolizer (IM) and extensive metabolizer (EM), respectively; 5-HT2A ROs were 96.4%, 97.2% and 98.4% for CYP2D6 PM, IM and EM, respectively; PANSS changes from placebo were -5.3, -7.7 and -11.3 for CYP2D6 PM, IM and EM, respectively; SAS changes from placebo were 0.13, 0.15 and 0.18 for CYP2D6 PM, IM and EM, respectively. The predictions of human D2, 5-HT2A RO, PANSS and SAS changes for risperidone with CYP2D6 genetic polymorphisms were well in line with the reported values in clinic. 5.0, 4.0 and 2.5 mg/day were the equivalent dosages of risperidone for CYP2D6 PM, IM and EM, respectively. The optimized maintenance therapy of risperidone was provided through the Three-Step method and the dosage range was 2.5-5.0 mg/day for three CYP2D6 gene groups in the present study. Taken together, our findings demonstrate that this extended translational framework not only differentiates the effects of CYP2D6 genetic polymorphisms on target occupancies and clinical outcomes, but also constitutes a scientific basis to optimize the maintenance therapy of neuropsychiatric patients in clinic." @default.
• W2894985356 created "2018-10-12" @default.
• W2894985356 creator A5027862495 @default.
• W2894985356 creator A5033868217 @default.
• W2894985356 creator A5039123294 @default.
• W2894985356 creator A5075706135 @default.
• W2894985356 date "2018-11-01" @default.
• W2894985356 modified "2023-09-27" @default.
• W2894985356 title "Optimization of maintenance therapy of Risperidone with CYP2D6 genetic polymorphisms through an extended translational framework-based prediction of target occupancies/clinical outcomes" @default.
• W2894985356 cites W1275714076 @default.
• W2894985356 cites W1507969477 @default.
• W2894985356 cites W1940764637 @default.
• W2894985356 cites W1964688493 @default.
• W2894985356 cites W1967318659 @default.
• W2894985356 cites W1972911248 @default.
• W2894985356 cites W1975514455 @default.
• W2894985356 cites W1978144911 @default.
• W2894985356 cites W1983958707 @default.
• W2894985356 cites W1985674713 @default.
• W2894985356 cites W1986157879 @default.
• W2894985356 cites W1987740956 @default.
• W2894985356 cites W1998001503 @default.
• W2894985356 cites W1998201540 @default.
• W2894985356 cites W2007592718 @default.
• W2894985356 cites W2012554561 @default.
• W2894985356 cites W2016652992 @default.
• W2894985356 cites W2017107943 @default.
• W2894985356 cites W2025944036 @default.
• W2894985356 cites W2029986378 @default.
• W2894985356 cites W2029995473 @default.
• W2894985356 cites W2030481736 @default.
• W2894985356 cites W2031524325 @default.
• W2894985356 cites W2033610699 @default.
• W2894985356 cites W2034861437 @default.
• W2894985356 cites W2042316297 @default.
• W2894985356 cites W2043985392 @default.
• W2894985356 cites W2048766195 @default.
• W2894985356 cites W2064795982 @default.
• W2894985356 cites W2064828122 @default.
• W2894985356 cites W2065409386 @default.
• W2894985356 cites W2066464642 @default.
• W2894985356 cites W2068443264 @default.
• W2894985356 cites W2069849124 @default.
• W2894985356 cites W2070619693 @default.
• W2894985356 cites W2079666511 @default.
• W2894985356 cites W2080872700 @default.
• W2894985356 cites W2083252023 @default.
• W2894985356 cites W2084515830 @default.
• W2894985356 cites W2086451647 @default.
• W2894985356 cites W2090187096 @default.
• W2894985356 cites W2090291844 @default.
• W2894985356 cites W2099185967 @default.
• W2894985356 cites W2104058573 @default.
• W2894985356 cites W2111292428 @default.
• W2894985356 cites W2122995608 @default.
• W2894985356 cites W2126097234 @default.
• W2894985356 cites W2128527026 @default.
• W2894985356 cites W2145619523 @default.
• W2894985356 cites W2152290963 @default.
• W2894985356 cites W2154180317 @default.
• W2894985356 cites W2155342545 @default.
• W2894985356 cites W2161570416 @default.
• W2894985356 cites W2164207356 @default.
• W2894985356 cites W2167218562 @default.
• W2894985356 cites W2167573026 @default.
• W2894985356 cites W2167715051 @default.
• W2894985356 cites W2170726480 @default.
• W2894985356 cites W2284698163 @default.
• W2894985356 cites W2312416758 @default.
• W2894985356 cites W2320451520 @default.
• W2894985356 cites W4319425390 @default.
• W2894985356 doi "https://doi.org/10.1016/j.phrs.2018.09.030" @default.
• W2894985356 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30281999" @default.
• W2894985356 hasPublicationYear "2018" @default.
• W2894985356 type Work @default.
• W2894985356 sameAs 2894985356 @default.
• W2894985356 citedByCount "2" @default.
• W2894985356 countsByYear W28949853562019 @default.
• W2894985356 countsByYear W28949853562020 @default.
• W2894985356 crossrefType "journal-article" @default.
• W2894985356 hasAuthorship W2894985356A5027862495 @default.
• W2894985356 hasAuthorship W2894985356A5033868217 @default.
• W2894985356 hasAuthorship W2894985356A5039123294 @default.
• W2894985356 hasAuthorship W2894985356A5075706135 @default.
• W2894985356 hasConcept C104317684 @default.
• W2894985356 hasConcept C111113717 @default.
• W2894985356 hasConcept C112705442 @default.
• W2894985356 hasConcept C118552586 @default.
• W2894985356 hasConcept C126322002 @default.
• W2894985356 hasConcept C135763542 @default.
• W2894985356 hasConcept C143998085 @default.
• W2894985356 hasConcept C2776412080 @default.
• W2894985356 hasConcept C2779727114 @default.
• W2894985356 hasConcept C2780057945 @default.
• W2894985356 hasConcept C2780135775 @default.
• W2894985356 hasConcept C2908647359 @default.
• W2894985356 hasConcept C33664856 @default.
• W2894985356 hasConcept C526171541 @default.

• next